(secondQuint)PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation.

 Randomized, double blind, placebo controlled, prospective trial in patients, receiving a kidney transplantation.

 Patients will be randomized to receive either Epoetin Beta (Neorecormon; Roche) or placebo.

 The primary endpoint will be delayed graft function.

 The anticipated duration of this trial is 2 year and the target sample size is 60 patients per arm.

.

 PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation@highlight

Randomized, double blind, placebo controlled, prospective trial investigating the effect of erythropoietin in renal transplantation.

 The investigators postulate that erythropoietin reduces the risk of delayed graft function.

